Please assess the completion status of the following clinical trial:

Trial Title: Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During Ramadan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of T1DM using daily insulin~2. 18.0 to \< 65.0 years of age with body mass index 20.0 to \<35.0 kg/m2.~3. Having diabetes for ≥2.0 years~4. HbA1c \<8.5%~5. Has a smart phone with access to the internet and welling to upload data during the study period.~6. Welling to wear a devise such as continuous glucose monitor ≥6 days/week.~7. Females, not currently known to be pregnant~8. In good general health as evaluated by investigator based on available clinical data~9. Willing to comply to the protocol requirements for the duration of the study~Exclusion Criteria:~1. Any history of more than one severe hypoglycemic episode (need assistance by third party) in the past 12 months~2. Any history of more than one episode of diabetic ketoacidosis in the past 12 months~3. Female pregnant or planning to get pregnant.~4. Use of any of the following medications: oral hypoglycemic agents, systemic corticosteroids or beta-blocker, theophylline, beta-adrenergic agonists, 1st generation anticholinergic drugs.~5. History of hypersensitivity to glucagon or severe hypersensitivity reactions (such as angioedema) to any other medications~6. History of uncontrolled hypertension (systolic BP \>160 mmHg or diastolic BP \>100 mmHg)~7. History of seizure disorder.~8. Presence of any of conditions based on judgment of the investigator that could affect or interfere with the response, absorption, metabolism or execration of glucagon.~9. Currently following any kind of weight-loss diet~10. Currently participation in another clinical trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Glucagon injection (Type: EXPERIMENTAL): Dilute Glucagon (1 mg/ml)
- Glucose tablets (Type: ACTIVE_COMPARATOR): Dextrose glucose tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).